CNTGF — Crown LiquidationCo NV in liquidatie Share News
0.000.00%
Last trade - 00:00TechnologySpeculativeMicro Cap
- $3.48m
- $74.53m
- €48.54m
Brief: Centogene Regains Compliance With Nasdaq Listing Requirements
Brief: Centogene And Denali Therapeutics Extend Observational Study On Parkinson’s Disease Genetics
Brief: Premier Research And Centogene Launch Strategic Partnership To Accelerate And De-Risk Rare Disease Clinical Development
Brief: Centogene Reports Second Quarter And First Half 2022 Financial Results
Brief: Centogene NV Receives Nasdaq Non-Compliance Notice
H.C. Wainwright initiates Centogene with 'buy' rating
Brief: Centogene Announces Changes To Supervisory Board, Including Appointment Of Mary Sheahan
Brief: Centogene Launches Rare And Neurodegenerative Disease Biodata Network
Brief: Centogene Reports First Quarter 2022 Financial Results
Brief: Centogene Announces Shareholder Approval Of All Resolutions At 2022 Annual General Meeting
Brief: Centogene Announces Appointment Of Miguel Coego Rios As Chief Financial Officer
Brief: Centogene, Agios Expand Partnership For Clinical Development Of Pyrukynd (Mitapivat) To Treat Children With Rare Blood Disease
Brief: Centogene's Centocloud Is Now CE-Marked As One Of The Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
Brief: Centogene And Takeda Extend Market Access And Expansion Partnership To Advance Patient Care Globally
Brief: Centogene Reports Q4 Results
Centogene NV rises on expansion of agreement with Pfizer
Brief: Centogene Announces Expansion Of Data Access, Collaboration Agreement With Pfizer
Brief: Centogene Joins Forces With Insilico Medicine For Niemann-Pick Disease Type C Target Discovery
NASDAQ RESUMED AT 11:30 AM